Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 9/20 | 0.69 |
| ▸ | PARP11 | Q9NR21 | 9/20 | 0.69 |
| ▸ | GRM5 | P41594 | 2/20 | 0.67 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.67 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.52 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 2/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8161680 | 0.87 | PARP11 (0.68) | PARP10PARP11GRM5MAPKAPK2PARP1 | |
| SCHEMBL8323443 | 0.84 | GRM5 (0.67) | PARP10PARP11GRM5MAPKAPK2PARP1 | |
| SCHEMBL379341 | 0.84 | GRM5 (0.67) | PARP10PARP11GRM5MAPKAPK2PARP1 | |
| SCHEMBL12230826 | 0.83 | PARP10 (0.56) | PARP10PARP11GRM5MAPKAPK2PARP1 | |
| SCHEMBL8156296 | 0.82 | PARP10 (1.00) | PARP10PARP11GRM5MAPKAPK2PGR | |
| SCHEMBL8155722 | 0.81 | PARP11 (1.00) | PARP10PARP11GRM5PARP1PDPK1 | |
| SCHEMBL504530 | 0.81 | GRM5 (1.00) | PARP10PARP11GRM5MAPKAPK2 | |
| SCHEMBL20956992 | 0.80 | TNIK (0.56) | MAPKAPK2CHEK1CD274PGR | |
| SCHEMBL3989419 | 0.80 | CYP11B1 (0.55) | MAPKAPK2CHEK1CD274 | |
| SCHEMBL29546603 | 0.79 | PGR (0.54) | PARP10PARP11GRM5MAPKAPK2CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034806-B2 | Bicyclic mGluR5 positive allosteric modulators and methods of making and using same | VANDERBILT UNIVERSITY (US) | 2011-10-11 | — | — | US | disclosed |
| US-20090270362-A1 | BICYCLIC MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY | 2009-10-29 | — | — | US | disclosed |
| WO-2008151184-A1 | BENZAMIDE MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY (US) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270362-A1 | BICYCLIC MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | GRM5, GRIK5, GRM1 | PARP10 2146/4885PARP11 3085/4885GRM5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.